Partnering, Pharma

Presidio commences out-licensing PPI-668

Posted on 11 November 2014

Tags: ,

Pharco and Presidio have entered into an exclusive license agreement for Presidio’s HCV NS5A inhibitor PPI-668 for development and commercialization to treat HCV infection in Egypt.

This exclusive license includes an opportunity for Pharco to expand its licensed territory to one or more additional countries in the MENA region.

Pharco will fund clinical development and commercialization of PPI-668 in Egypt, and potentially the MENA region.

Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Egypt and potentially the MENA region.

Pharco made an equity investment in Presidio related to the license agreement.

Ascletis and Presidio have entered into an exclusive licensing agreement for Presidio’s clinical stage, HCV NS5A inhibitor PPI-668, also known as ASC16.

The agreement provides Ascletis with exclusive rights to develop and commercialize PPI-668 in Greater China.

Presidio will retain all rights in the rest of the world.

Ascletis will fund clinical development, manufacturing and commercialization of PPI-668 in greater China and Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Greater China.

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

Print Friendly, PDF & Email

Leave a Reply